contractpharmaApril 17, 2019
Tag: AAV , cevec , adeno , Viral , Medical
CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.
The funding will be allocated to the expansion and commercialization of CEVEC’s CAP GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.
"We are extremely encouraged and would like to thank our new and existing investors for their confidence shown in CEVEC with this financing round, which came at such an important stage of development for the Company," said Dr. Nicole Faust, chief executive officer and chief scientific officer of CEVEC. "This round of financing is a critical milestone in our Company’s history, helping us to expand and commercialize our proprietary stable AAV vector production process. In addition, it will also enable us to extend our technology to other viral vectors including lentivirus. This will open the field for a wide range of medical indications and will close the manufacturing gap for gene therapy viral vectors. The technology has the potential to completely change the way viral vectors are produced."
CEVEC is the first and only company today to offer a solution to make the production of AAV vectors as easy as the production of monoclonal antibodies. The platform technology is now being upscaled to industrial scale and commercialized with leading companies in the gene therapy sector.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: